Abstract
“Biomarkers have the potential to revolutionise the diagnosis of disease
and the drug discovery process”
Part of Espicom' s new 3-volume report on Cancer, CNS and Cardiovascular
Biomarkers, this volume provides a comprehensive analysis of the CNS biomarker
sector, along with a critical assessment of the companies involved.
By 2015, we estimate the global CNS biomarker market will account for around
15% of global biomarker sales to be worth over US$3.4 billion as the market
matures; driven by growth in clinical biomarkers for neurodegenerative
diseases, the development of biomarkers for neuropsychiatric diseases (e.g.
schizophrenia and depression) for clinical trial guidance and the
commercialisation of the first molecular tests to predict AD and MCI and to
differentiate MS patients. 57% of the market will be taken by the biomarker
discovery sector.
The majority of the CNS biomarker research at the present time is aimed at the
discovery and identification of biomarker signatures through the application
of gene expression profiling, protein profiling and/or metabolomics, as well
as the use of imaging and electrophysiological surrogate biomarkers. Many
"probable" biomarker signatures are now under evaluation, particularly in AD,
MS and schizophrenia.
This market is immature as CNS disorders are often ill-defined and their
underlying aetiology poorly understood. However, in certain areas such as
neurodegenerative diseases, a clear genetic component has been established and
significant strides have been made in discovering and identifying novel
biomarkers to guide drug development programmes and/or as diagnostic aids.
The CNS biomarker market represents one of the smallest segments of biomarkers
in terms of revenue as relatively few CNS biomarkers are commercially
available. In 2007, we estimate the CNS biomarker market accounted for less
than 5% of biomarker revenues, with the majority coming from biomarker
discovery in schizophrenia and neurodegenerative disorders.
Collaboration between the industry and academia is critical if the potential
of CNS biomarkers is to be realised. During the last ten years several
public-private partnerships have been established to discover biomarkers and
their uses in the diagnosis of CNS disorders. According to PhRMA, around US$44
.5 billion was spent on R&D. However, there is still only an 8% chance that a
drug entering clinical trials will reach the market. Reliable read-outs are
essential if the industry is to improve its track record on drug attrition and
continue to attract investment.
Companies Analysed
- Affymetrix
- Applied NeuroSolutions Inc
- Banyan Biomarkers
- BG Medicine
- BioSite Inc
- Biospective
- Celera
- Clinical Data Inc
- Curidium Medica Plc
- DigiLabs Peptidomics
- EnVivo Pharmaceuticals
- Innogenetics NV
- KineMed Inc
- Lipomics Technologies
- Luminex Corporation
- Memory Pharmaceuticals Corporation
- Metabolon Inc
- Nanogen Inc
- Nanosphere Inc
- Nymox Pharmaceutical Corporation
- Osta Biotechnologies
- PDD Inc
- Phenomenome Discoveries Inc
- Power3 Medical Products
- Provista Life Sciences
- Psynova Neurotech Ltd
- Satoris Inc
- Siemens Medical Solutions
- SuperArray Bioscience Corporation
| 
View Cart
